09/06/2024 | Press release | Distributed by Public on 09/06/2024 09:34
Kirkland & Ellis advised Platinum Equity on the debt financing for its acquisition of a controlling stake in Mumbai-based generic pharmaceutical business Inventia Healthcare Limited's core Oral Solid Dosage business (Inventia) from India Life Sciences Fund III (advised by InvAscent), NYLIM Jacob Ballas India Fund III, LLC, Mauritius and affiliates of the company's founding Shah family. The Shah family is retaining a minority stake in Inventia. Inventia serves as a partner to over 100 customers supplying both semi-finished and finished OSD formulations for both regular and value-added generics. Inventia's partners include global and leading local pharmaceuticals companies that sell in more than 40 countries across North America, South America, Europe, Southeast Asia, Middle East and Africa.
The Kirkland team was led by debt finance partners Manas Chandrashekar and John Curran and associate Ryan Chan.